94 related articles for article (PubMed ID: 8172827)
1. Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease.
Trümper L; Jung W; Dahl G; Diehl V; Gause A; Pfreundschuh M
Ann Oncol; 1994; 5 Suppl 1():93-6. PubMed ID: 8172827
[TBL] [Abstract][Full Text] [Related]
2. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease.
Gorschlüter M; Bohlen H; Hasenclever D; Diehl V; Tesch H
Ann Oncol; 1995 May; 6(5):477-82. PubMed ID: 7545429
[TBL] [Abstract][Full Text] [Related]
3. The clinical significance of cytokines and soluble forms of membrane-derived activation antigens in the serum of patients with Hodgkin's disease.
Gause A; Jung W; Keymis S; Schobert I; Scholz R; Schmits R; Diehl V; Pohl C; Hasenclever D; Pfreundschuh M
Leuk Lymphoma; 1992 Aug; 7(5-6):439-47. PubMed ID: 1283546
[TBL] [Abstract][Full Text] [Related]
4. The significance of serum levels of soluble 60kDa receptors for tumor necrosis factor in patients with Hodgkin's disease.
Gruss HJ; Dölken G; Brach MA; Mertelsmann R; Herrmann F
Leukemia; 1993 Sep; 7(9):1339-43. PubMed ID: 8396696
[TBL] [Abstract][Full Text] [Related]
5. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
[TBL] [Abstract][Full Text] [Related]
7. Serum concentrations of cytokines in patients with Hodgkin's disease.
Blay JY; Farcet JP; Lavaud A; Radoux D; Chouaïb S
Eur J Cancer; 1994; 30A(3):321-4. PubMed ID: 8204352
[TBL] [Abstract][Full Text] [Related]
8. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease.
Seymour JF; Talpaz M; Hagemeister FB; Cabanillas F; Kurzrock R
Am J Med; 1997 Jan; 102(1):21-8. PubMed ID: 9209197
[TBL] [Abstract][Full Text] [Related]
9. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease.
Bohlen H; Kessler M; Sextro M; Diehl V; Tesch H
Ann Hematol; 2000 Mar; 79(3):110-3. PubMed ID: 10803931
[TBL] [Abstract][Full Text] [Related]
10. Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma.
Fischer M; Bijman M; Molin D; Cormont F; Uyttenhove C; van Snick J; Sundström C; Enblad G; Nilsson G
Leukemia; 2003 Dec; 17(12):2513-6. PubMed ID: 14562126
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas.
Warzocha K; Salles G; Bienvenu J; Barbier Y; Bastion Y; Doche C; Rieux C; Coiffier B
Leukemia; 1997 Apr; 11 Suppl 3():441-3. PubMed ID: 9209418
[TBL] [Abstract][Full Text] [Related]
12. Increased levels of circulating interleukin-6 in patients with Hodgkin's disease.
Gause A; Scholz R; Klein S; Jung W; Diehl V; Tesch H; Hasenclever D; Pfreundschuh M
Hematol Oncol; 1991; 9(6):307-13. PubMed ID: 1748397
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma.
Gause A; Jung W; Schmits R; Tschiersch A; Scholz R; Pohl C; Hasenclever D; Diehl V; Pfreundschuh M
Ann Oncol; 1992 Sep; 3 Suppl 4():49-52. PubMed ID: 1333270
[TBL] [Abstract][Full Text] [Related]
14. Serum soluble tumour necrosis factor receptor 55 is increased in patients with haematological neoplasias and is associated with immune activation and weight loss.
Denz H; Orth B; Weiss G; Gallati H; Herrmann R; Huber P; Wachter H; Fuchs D
Eur J Cancer; 1993; 29A(16):2232-5. PubMed ID: 8110491
[TBL] [Abstract][Full Text] [Related]
15. [Measurement of five cytokines in the serum of malignant lymphoma patients].
Zhu H; Wang Y; Han X
Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):85-8. PubMed ID: 10921109
[TBL] [Abstract][Full Text] [Related]
16. Increased levels of circulating cytokines in patients with untreated Hodgkin's disease.
Gause A; Keymis S; Scholz R; Schobert I; Jung W; Diehl V; Pohl C; Pfreundschuh M
Lymphokine Cytokine Res; 1992 Apr; 11(2):109-13. PubMed ID: 1581417
[TBL] [Abstract][Full Text] [Related]
17. Soluble molecules as biological markers in Hodgkin's disease.
Nadali G; Vinante F; Chilosi M; Pizzolo G
Leuk Lymphoma; 1997 Dec; 26 Suppl 1():99-105. PubMed ID: 9570686
[TBL] [Abstract][Full Text] [Related]
18. Soluble ICAM-1 in Hodgkin's disease: a promising independent predictive marker for survival.
Christiansen I; Enblad G; Kälkner KM; Gidlöf C; Glimelius B; Tötterman TH
Leuk Lymphoma; 1995 Oct; 19(3-4):243-51. PubMed ID: 8535215
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels of TNF alpha and TNF receptor superfamily members in lymphoid neoplasia.
Metkar SS; Naresh KN; Manna PP; Srinivas V; Advani SH; Nadkarni JJ
Am J Hematol; 2000 Oct; 65(2):105-10. PubMed ID: 10996826
[TBL] [Abstract][Full Text] [Related]
20. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Mounier N; Brice P; Divine M; Morschhauser F; Gabarre J; Blay JY; Voillat L; Lederlin P; Stamatoullas A; Bienvenu J; Guiguet M; Intrator L; Grandjean M; Brière J; Ferme C; Salles G;
J Clin Oncol; 2007 May; 25(13):1732-40. PubMed ID: 17389336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
